The development of the conditions for vortioxetine isolation from biological fluids
Keywords:vortioxetine, biological fluids, extraction, UV spectrophotometry
The chemical-toxicological significance of antidepressant drugs is steadily increasing. The development of effective methods of the sample preparation of the biological material is an important analytical aspect in toxicology of the newgeneration antidepressants.
Aim. To develop the conditions for the sample preparation of biological fluids in order use them in the chemicaltoxicological analysis of the new antidepressant vortioxetine.
Materials and methods. The studies were performed with model blood and urine samples spiked with vortioxetine. When examining the blood the formed blood elements were pre-precipitated by adding 10 % solution of trichloroacetic acid. The extraction purification was performed with hexane at pH 1-2, and the drug was extracted from the biological
fluids with methylene chloride at pH 8-9. The extracts obtained were further subjected to TLC purification. Vortioxetine in eluates from chromatograms was determined by the UV-spectrophotometric method.
Results and discussion. The Rf value of vortioxetine in the mobile phase of ethyl acetate-methanol-25 % ammonium hydroxide solution (85 : 10 : 5) was 0.77 ± 0.05. The UV spectra of the eluates from the chromatograms had absorption maxima at the wavelengths of 229 ± 2 and 232 ± 2 nm and matched with the UV spectrum of the standard solution of vortioxetine in methanol. The quantitative determination was performed at λmax232 nm by the equation of the calibration curve y = (0.0172 ± 3 · 10-4)x + (0.027 ± 0.008). Under the conditions of the sample preparation developed 27 ± 1 % of vortioxetine from the blood and 62 ± 2 % of the drug from the urine were isolated.
Conclusions. The efficiency of the sample preparation of biological fluids by the method of liquid-liquid extraction in relation to the new antidepressant vortioxetine has been determined. The methods developed are recommended for use in forensic and clinical toxicology.
1. Sanchez, C., Asin, K. E., Artigas, F. (2015). Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics, 145, 43–47. doi: https://doi.org/10.1016/j.pharmthera.2014.07.001.
2. Garnock-Jones, K. P., Lyseng-Williamson, K. A. (2015). Vortioxetine in major depressive disorder: a guide to its use in the EU. Drugs & Therapy Perspectives, 31, 221–228. doi: https://doi.org/10.1007/s40267-015-0217-x.
3. Orsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Vellante, F., Fornaro, M., Fiengo, A., Mazza, M., Vecchiotti, R., Perna, G., de Bartolomeis, A., Martinotti, G., Giannantonio, M. D., De Berardis, D. (2016). New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics, 16 (5), 483–495. doi: https://doi.org/10.1586/14737175.2016.1173545.
4. Chen, G., Lee, R., Højer, A. M., Buchbjerg, J. K., Serenko, M., Zhao, Z. (2013). Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant. Clinical Drug Investigation, 33, 727–736. doi: https://doi.org/10.1007/s40261-013-0117-6.
5. Mazza, M. G., Rossetti, A., Botti, E. R., Clerici, M. (2018). Vortioxetine overdose in a suicidal attempt: A case report. Medicine (Baltimore), 97 (25), 10788. doi: https://doi.org/10.1097/MD.0000000000010788.
6. Wróblewski, K., Petruczynik, A., Buszewski, B., Szultka-Młyńska, M., Karakuła-Juchnowicz, H., Waksmundzka-Hajnos, M. (2017). Determination of Vortioxetine in human serum and saliva samples by HPLC–DAD and HPLC–MS. Acta Chromatographica, 29 (3), 325–344. doi: https://doi.org/10.1556/1326.2017.29.3.02.
7. Qin, M., Qiao, H., Yuan, Y., Shao, Q. (2018). A quantitative LC–MS/MS method for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma, and its application to toxicokinetic study. Analytical Methods, 10 (9), 1023–1031. doi: https://doi.org/10.1039/C7AY02642K.
8. Er-min, G., Chengke, H., Bingqing, L., Lingjing, Y., Tian, L., Guoxin, H., Hongyu, Z. (2015). An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 997, 70–74. doi: 10.1016/j.jchromb.2015.05.010.
9. Moffat, A. C., Osselton, M. D., Widdop, B. (2011). Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. (4-th ed.). London, Chicago: Pharmaceutical Press, 2736.
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).